Rivista Nr. 1/2025
Pagine 8-12: Una diagnosi difficile
Neurology Clinical Practice 14 (2024): A General Neurologist's Practical Diagnostic Algorithm for Atypical Parkinsonian Disorders
www.neurology.org/doi/10.1212/CPJ.0000000000200345
Pagina 14: Nuove speranze per la terapia con anticorpi
Nature Medicine 30 (2024): Sustained effect of prasinezumab on Parkinson’s disease motor progression in the open-label extension of the PASADENA trial
www.nature.com/articles/s41591-024-03270-6
Deutsche Gesellschaft für Parkinson und Bewegungsstörungen (Oktober 2024): Neue Hinweise auf Langzeitwirkung von Prasinezumab bei Parkinson – weitere placebokontrollierte Studien erwartet
Medienmitteilung Roche (Dezember 2024): Roche’s Phase IIb study of prasinezumab missed primary endpoint, but suggests possible benefit in early-stage Parkinson’s disease
www.roche.com/media/releases/med-cor-2024-12-19
Pagina 15: Diagnosi precoce grazie alla lingua
npj Parkinson's Disease 10 (2024): Unveiling early signs of Parkinson’s disease via a longitudinal analysis of celebrity speech recordings
www.nature.com/articles/s41531-024-00817-9
Stimolare il nervo vago?
npj Parkinson's Disease 10 (2024): Vagus nerve stimulation in Parkinson’s disease: a scoping review of animal studies and human subjects research
www.nature.com/articles/s41531-024-00803-1
©2025 Parkinson Svizzera